NCT04138277: A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

Sponsor: Amicus Therapeutics. Phase: PHASE3. Conditions: Pompe Disease (Late-onset)